Acarix announces preliminary outcome in oversubscribed rights issue
Malmö, Sweden September 9, 2020
Acarix announces preliminary outcome in oversubscribed rights issue
INSIDE INFORMATION: The preliminary result of the rights issue in Acarix AB (”Acarix” or the “Company”), in which the subscription period ended on 8 September 2020, indicates that a total of 105,414,911 shares have been subscribed or registered for subscription in the rights issue, which corresponds to approximately 122 percent of the rights issue. Thus, the preliminary results show that the rights issue has been oversubscribed.
The preliminary result of the rights issue in Acarix, in which the subscription period took place from and including 21 August 2020 up to and including 8 September 2020, indicates that 66,052,303 shares have been subscribed for with subscription rights, which corresponds to approximately 76.7 percent of the rights issue. In addition, the Company has received applications to subscribe for 39,362,608 shares without subscription rights, corresponding to approximately 45.7 percent of the rights issue. Accordingly, in total 105,414,911 shares have been subscribed or registered for subscription in the rights issue, which corresponds to approximately 122 percent of the rights issue.
Notice of allotment
Those who have subscribed for shares without use of subscription rights will be allotted shares in accordance with the principles for allotment set out in the prospectus which has been prepared for purposes of the Rights Issue. Notice of potential allotment of shares subscribed for without use of subscription rights will be provided through the distribution of a settlement note. Payment shall be made no later than three (3) banking days following issuance of the settlement note. Those who have not been allotted shares will not receive any notification hereof. If payment is not made at the right time, the shares may be transferred to another party. Those who subscribe for shares without preferential rights through its nominee will receive notice of allotment in accordance with the nominee's procedures.
Number of shares, votes, share capital and dilution
Through the Rights Issue, Acarix share capital will increase by SEK 861,567.38 to SEK 1,378,507.81. The total number of shares and votes will increase by 86,156,738, from 51,694,043 to 137,850,781 shares and votes. For existing shareholders who did not subscribe for their pro rata share of the Rights Issue, a dilution of approximately 62.5 percent of the total number of shares and votes in the Company following the rights issue will arise. On or around seven days following the registration of the rights issue with the Swedish Companies Registration office, paid subscribed shares (BTA) will be converted into new shares without any specific notice from Euroclear Sweden. The new shares will be admitted to trading in connection with the BTAs conversion to shares, which is expected to take place around week 41, 2020.
Redeye AB is acting as financial adviser and Baker McKenzie is acting as legal adviser to Acarix in connection with the rights issue. Hagberg & Aneborn Fondkommission AB is acting as issuing agent.
This information is information that Acarix AB is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information in this press release has been published through the agency of the contact persons below at the time and date indicated by GlobeNewswire, the news distributor of Acarix AB, in conjunction with the publication of this press release. The persons below can also be contacted for further information.
Per Persson, VD Acarix AB,
+46 (0)73 600 59 90,
Christian Lindholm, CFO Acarix,
+46 (0)70 511 83 33,
Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readout is obtained in less than 10 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. Wildeco Ekonomisk Information AB (+46 8 545 271 00, firstname.lastname@example.org) is Certified Adviser to Acarix. For more information please visit www.acarix.com.
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else.
This press release is not a prospectus for the purposes the (EU) 2017/1129 Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. A prospectus, corresponding to an EU Growth prospectus including published supplements, has been prepared by the Company and published on the Company's web page.
This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Redeye is acting for Acarix in connection with the Rights Issue and no one else and will not be responsible to anyone other than Acarix for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore, South Africa, the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Growth Market rule book for issuers.
Information to distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Acarix have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Acarix may decline and investors could lose all or part of their investment; the shares in Acarix offer no guaranteed income and no capital protection; and an investment in the shares in Acarix is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Acarix.
Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Acarix and determining appropriate distribution channels.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 202110.4.2021 14:30:00 CEST | Press release
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed EOS-448 showed preliminary signs of clinical activity as a monotherapy, including a partial response in one pembrolizumab-resistant melanoma patient, and stable disease in multiple patients EOS-448 reduced TIGIT+ suppressive T regulatory cells and CD8 T cells considered to be exhausted at all tested doses, indicating engagement of FcγR, an essential component in many immune system effector functions Company to advance EOS-448 into combination trials with pembrolizumab and other novel agents in both checkpoint-naïve and resistant patients Company to host conference call on Monday, April 12th at 8:00 a.m. EDT to discuss results CAMBRIDGE, Mass. and GOSSELIES, Belgium, April 10, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), clinical-stage biopharmaceutical company
Notice to Annual General Meeting 20219.4.2021 21:45:00 CEST | Press release
Shareholders in MICRO SYSTEMATION AB (publ) are hereby given notice to attend the Annual General Meeting (AGM) on Tuesday, 11 May 2021, at 18.00 at MSAB’s premises at Hornsbruksgatan 28 in Stockholm. Registration for the AGM will commence at 17:15. Because of COVID-19 (the Corona virus), MSAB is prioritising health and safety and has thus decided to hold the AGM on Company premises, Hornsbruksgatan 28 in Stockholm, and keep the meeting as brief as possible and to provide the opportunity for shareholders to also vote by post. No food will be served. The demonstration and display of the Company’s products normally given in conjunction with the AGM are cancelled. Questions for Company management can be sent to email@example.com. Against the backdrop of recommendations issued by Swedish authorities, all shareholders are encouraged to consider utilising the possibility of voting by mail via a form which will be available on the Company’s website (www.msab.com/investors) rather than physically a
Kallelse till årsstämma 20219.4.2021 21:45:00 CEST | Pressemelding
Aktieägare i MICRO SYSTEMATION AB (publ) kallas härmed till årsstämma tisdagen den 11 maj 2021 kl. 18.00 i MSABs lokaler på Hornsbruksgatan 28 i Stockholm. Inregistrering till årsstämman börjar klockan 17:15. Med anledning av COVID-19 (Corona-viruset) har MSAB, för att sätta hälsa och säkerhet i första rummet, beslutat att hålla stämman i bolagets lokaler, Hornsbruksgatan 28 i Stockholm och att korta stämman så långt som möjligt, samt ge aktieägarna möjlighet att före stämman utöva sin rösträtt per post. Någon servering kommer inte att förekomma. Demonstration och visning av bolagets produkter som normalt görs i samband med stämman är inställd. Frågor till bolagsledningen kan skickas till firstname.lastname@example.org . Mot bakgrund av myndigheternas föreskrifter uppmanas alla aktieägare att överväga att istället för att närvara fysiskt vid stämman utnyttja möjligheten att poströsta via formulär på bolagets hemsida www.msab.com/investors. RÄTT TILL DELTAGANDE Aktieägare i Micro Systemation AB (publ),
RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag9.4.2021 18:43:18 CEST | Press release
Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 09 April 2021, purchased 9 shares of RomReal at NOK 1.75 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,475,739 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
CONDITIONS FOR PURCHASES OF CORPORATE BONDS9.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-14BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: VATTENFALL AB: XS0328561286, 2022-11-01 STANGASTADEN AB: SE0012193860, 2024-09-27 HEBA FASTIGHETS AB: SE0013882875, 2026-03-02 SWEDISH MATCH AB: XS1619638528, 2022-05-30 SWEDISH MATCH AB: XS2306815114, 2026-02-24 SVENSKA CELLULOSA AB SCA: SE0013882560, 2025-09-23 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-03-14Bid date2021-04-14Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS0328561286: 30 mln SEK +/-30 mln SEK SE0012193860: 30 mln SEK +/-30 mln SEK SE0013882875: 30 mln SEK +/-30 mln SEK XS1619638528: 30 mln SEK +/-30 mln SEK XS2306815114: 30 mln SEK +/-30 mln SEK SE0013882560: 30 mln SEK +/-30 mln SEK Highest permi
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER9.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-14CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-10-14 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-04-02 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-04-14Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS9.4.2021 16:20:00 CEST | Press release
Bid procedure, 2021-04-16BondsSWEDISH GOVERNMENT: 1062. SE0013935319. 2031-05-12 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 KINGDOM OF SWEDEN: REGS, XS2226974504, 2030-09-09 Bid date2021-04-16Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1062: 750 mln SEK +/-400 mln SEK 1053: 500 mln SEK +/-250 mln SEK REGS: 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1062: 750 mln SEK per bid 1053: 500 mln SEK per bid REGS: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-04-20Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-04-09 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation